RBMA Washington Insider - October 18, 2017
1. Last Week in Review
The   Senate had the week off from Washington, leaving the House to conduct a   modest slate of legislative  business. Most notably, House lawmakers advanced a $36.5 billion   disaster relief package in a 353-69 vote under suspension of the rules.   The bill represents the second installment of aid since a series of   natural disasters struck southeast Texas, Florida, and  Puerto Rico, among other areas. The breakdown of funds includes $18.7   billion for the Federal Emergency Management Agency’s disaster relief   fund, $576.5 million for wildfire recovery, and $16 billion to keep the   National Flood Insurance Program (NFIP) afloat. 
The   White House made significant headlines in the healthcare and foreign   policy arenas this week  as President Trump made a series of announcements on Thursday and   Friday. Specifically, the White House released an executive order on   Thursday that would encourage the creation of cheaper health plans that   do not abide by many of the consumer protections and  benefit rules prescribed by the Affordable Care Act (ACA). That   executive order was followed shortly by the announcement that the White   House intends to end disbursing the cost-sharing reduction payments that   help subsidize coverage for low-income individuals.  A full breakdown on both developments are included in the roundup below.
On   Friday, President Trump took the controversial step of “de-certifying”   Iran’s compliance with  the multi-nation nuclear deal struck in 2015 that involved lifting   economic sanctions in return for controls on Iran’s nuclear development.   The move is a step short of withdrawing the United States from the   deal, although the President has threatened he would  “terminate the deal” should Congress not approve “satisfactory” changes.   What remains unknown is whether Iran – and the other members of the   international negotiating team – will recognize the American demands as   legitimate. Importantly, and despite President  Trump’s assertions, the international observers monitoring Iran’s   nuclear program have insisted that the nation remains in compliance with   the deal’s terms.  
2. Trump  Issues Executive Order Setting Path to Expand Association Health Plans, Short-Term Plans, HRAs
Last Thursday, President Trump signed an Executive Order (EO) that seeks to broaden the availability of   Association Health Plans (AHPs); expand the definition of short-term   limited duration insurance (STLDI) policies; and change Health   Reimbursement Arrangements (HRA). It is important to note that  this EO likely does not have an immediate legal effect. The order   instructs the Department of Health and Human Services (HHS), Treasury,   and Department of Labor (DOL) to “consider” the proposed policies, for   which implementation would likely necessitate formal  notice and comment rulemaking. Many commenters have highlighted that   broadening access to AHPs and STLDI amounts to a “workaround” to ACA   coverage requirements, which could have a significant destabilizing   impact on the individual and small group market if  healthier people are drawn to these alternative options.
Last   week’s EO instructed the DOL to consider reinterpreting AHPs as the   type of insurance subject  to insurance requirements that apply to large group plans under the   Employee Retirement Income Security Act (ERISA), which are not subject   to ACA essential health benefits (EHB) and actuarial value (AV)   requirements. The Administration notes that the proposal  is aimed at providing small business workers with a broader range of   insurance options at lower rates in the large group market. The   Administration elaborates that “a broader interpretation [of ERISA]   could potentially allow employers in the same line of business  anywhere in the country” to form AHPs across state lines. The   Administration says employers would not be able to exclude employees   from the plan or set premiums based on health status. 
In   the EO, the President directs the agencies to consider expanding access   to STLDI.  The Obama  Administration had restricted such plans to a duration of three months,   with enforcement taking effect on April 1, 2017. The EO notes that STLDI   is not subject to ACA rules and estimates that it costs one-third the   premium of ACA-compliant coverage. According  to the Administration, STDI nonetheless may have “broad provider   networks and high coverage limits.” It is unclear whether STLDI policies   ultimately would be considered minimum essential coverage and satisfy   the individual mandate penalty.
The   EO further directs the agencies to consider modifications to HRAs “so   employees can better  use them for their employees.” The Administration notes that “expanded   HRAs could potentially give American workers greater flexibility and   control over how to finance their healthcare needs.” This could include   using employer-contributed, non-taxable HRA funds  toward individual market premiums, which had been restricted under the   Obama Administration. 
Congressional   reactions have fallen along predictable partisan lines. Senate Finance   Ranking Member  Ron Wyden (D-OR) said the EO “will undermine protections for those with   pre-existing conditions, segregate the market into sick and healthy, and   reopen the door to scam health insurance that doesn’t cover real care.”   House Energy and Commerce Chairman Greg  Walden (R-OR) and Health Subcommittee Chair Michael Burgess (R-TX),   meanwhile, welcomed the EO and said it would provide “more affordable   options.” 
3. CHIP Reauthorization May Not See Action Until December
Although   both Republicans and Democrats agree on a five-year reauthorization of   federal funding  for the Children’s Health Insurance Program and a phase-out of the 23   percent funding bump enacted under the Affordable Care Act (ACA), they   have hit a snag over how to pay for it. It wasn’t clear how close the   two sides were to an agreement on the $8.2 billion  in offsets as the Friday (Oct. 13) deadline set by Republicans for   negotiating the pay-fors loomed, but House Freedom Caucus Chair Mark   Meadows (R-NC) said he thinks House Republicans could pass CHIP funding   extension legislation without support from Democrats.  Republicans this past week said they would delay the floor vote on CHIP   in order to seek a compromise on offsets, and Energy & Commerce   Chair Greg Walden (R-OR) set the deadline after a long, contentious CHIP   markup by his committee.
As   questions and concerns arise over the timing of the now-expired funding   for the program, sources  report that House Republicans are looking to work out an offset deal   with Democrats because it would put pressure on the Senate to adopt the   House bill. Some are wondering whether Republicans were instead buying   time to convince members of their own party to  vote for the bill, but Rep. Meadows has indicated that was never a   problem. Additionally, sources confirmed last week that the Senate will   focus their time over the next four weeks on issues related to the   federal budget and tax reform, leaving no time for  a stand-alone health care bill. Many now suspect that the CHIP   legislation will most likely be part of a bigger “end of year” spending   package in December.
4. Administration Announces Decision to Pull CSRs
The Department of Health and Human Services (HHS) and the White House late Thursday announced that they would immediately discontinue Affordable Care Act (ACA)   cost-sharing reduction (CSR) payments. Despite its ambivalence over the   subsidies, the Administration has been deciding on a month-by-month   basis to make payments to insurers since it took over  in January. The legality of the CSR payments – which were authorized by   the ACA but never appropriated – has been the subject of a lawsuit   between the House of Representatives and the former (and now current)   Administration. The district court ruled in favor  of the House and the Obama Administration appealed the decision, but the   appeal has been on hold since President Trump took office. During that   time, 16 states have intervened to defend the previous Administration’s   position in the case out of fear that the  new Administration would no longer protect their interests.
As part of the decision to cut off payments, the Administration released a legal  opinion from the Justice Department finding that the CSR payments were illegal.   In the opinion, Attorney General Sessions notes that “although the   Department of Justice has  previously defended in court the government’s decision to use the   permanent appropriation [for the CSR payments], I have concluded that   the best interpretation of the law is that the permanent appropriation…   cannot be used to fund the CSR payments...” 
The Congressional Budget Office (CBO) in August estimated that cutting off the CSRs would “increase the federal deficit, on net,   by $194 billion from 2017 through 2026.” CBO reasoned that insurers   would seek to offset losses from the discontinuance of the CSRs by   raising premiums. The federal government would then  bear the brunt of the those premium increases by paying higher premium   subsidies. In addition to increasing the deficit, the Administration’s   decision raises important questions about the future stability of the   individual market. The higher premiums projected  by CBO could prompt individuals to leave the market or stop paying   premiums. When the CSR payments stop, insurers would be entitled under   their contracts with the federal government to withdraw from the   Exchanges. The decision also puts tremendous pressure  on Senate HELP Committee leaders to converge on a bipartisan agreement   to provide stable CSR funding, though objections from conservative   factions will be hard to overcome.
As   far as the legal implications of this decision, commenters have   highlighted the possibility  that states intervening in the ongoing litigation will ask the court to   prevent the Administration from cutting off payments. In addition, they point  out, insurers would be able to sue in the Court of Federal Claims to recoup the unpaid subsidies promised to them under the ACA.
5. Hargan to Serve as Acting HHS Secretary
On   Tuesday, the White House announced that President Trump had appointed   former corporate lawyer  and George W. Bush administration official Eric Hargan to be acting   Secretary of Health and Human Services (HHS). Hargan’s appointment comes   following the resignation of Tom Price, who vacated the post after   several Politico articles chronicled his travel costs while using private and government   planes. Trump announced that Hargan will now fill the role that Price   left behind as Republicans continue their ongoing efforts to repeal and   replace the Affordable Care Act.   
Hargan’s   previous experience at the HHS includes serving as deputy general   counsel, principal  associate deputy secretary, and acting deputy secretary under the Bush   administration. Just last week, the Senate backed Hargan’s nomination to   be HHS Deputy Secretary 57 to 38.  U.S. Food and Drug Commissioner   Scott Gottlieb was also reportedly considered  for the acting secretary position, but claimed he would better serve the   administration by remaining in his current role.
6. CMS Qualifying APM Participant Look-Up Tool Now Available
The Centers for Medicare & Medicaid Services (CMS) has unveiled  an interactive look-up tool where   2017 Advanced Alternative Payment Model (APM) participants can look up   their Qualifying APM Participant (QP) status. The tool released on Oct.  4 is based on calculations from claims with dates of service between   Jan. 1 and March 31 for the first QP determination “snapshot” period.   With this tool, you can determine your Merit-based Incentive Payment   System (MIPS) eligibility by simply entering a National  Provider Identifier (NPI) into the given field and clicking the “FIND QP   STATUS BY NPI” button. About 75,000 NPIs are included in this first QP   analysis. 
CMS will make QP determinations using three snapshot dates: March 31,   June 30 and Aug. 31. The tool will be updated soon with calculations for   the second QP snapshot period from claims with dates of services   between Jan. 1 and June 30. The third QP snapshot  period will occur for the period between Jan. 1 and Aug. 31. Under the   Quality Payment Program (QPP), eligible clinicians who meet certain   criteria are considered QPs in Advanced APMs and are excluded from the   MIPS quality reporting program. QPs identified  based on the 2017 performance year will receive a 5 percent lump sum   Medicare incentive payment in 2019. 
7. Harvey  L. Neiman Institute Awarded $3.7M Grant From NIH for Clinical Research Center
Harvey   L. Neiman Health Policy Institute has been awarded a five-year, $3.7   million grant from  the National Institutes of Health (NIH) to establish a core center for   clinical research to promote musculoskeletal clinical research. It will   be based at the University of Washington (UW). The new clinical research   center will be called the Clinical Learning,  Effectiveness and Research (CLEAR) Center and will be led by Jeffrey G.   Jarvik, MD, MPH, professor of radiology at UW Medicine. The intent of   the center is to improve methods for conducting clinical musculoskeletal   studies and provide analysis-ready data for  scientific investigators. 
As   a research partner of the CLEAR Center, the Neiman Institute will make   their extensive data  holdings available to investigators, most notably, the Centers for   Medicare & Medicaid Services (CMS) 5 percent research identifiable   files which contain all fee-for-service claims for a 5 percent national   sample of Medicare beneficiaries.
8. NIH Grants Penn Radiology $8.5M for Two International  Neuroimaging Associations
A   research group looking to discover brain changes associated with aging   and psychosis at the  Perelman School of Medicine at the University of Pennsylvania received   two grants from the National Institutes on Aging, National Institute of   Mental Health and general office of the Director of the National   Institutes of Health (NIH) equaling $8.5 million.  The funding will support two large multi-site international neuroimaging   consortia—one on brain aging and Alzheimer’s Disease (AD) and another   on psychosis, as well as a broader computing infrastructure for imaging   analytics and machine learning at Penn Medicine. 
The   researchers will aim to utilize machine learning methods and large   databases of imaging and  clinical data to discover brain changes associated with aging and   psychosis. They will also develop a “Brain Chart” that will allow   researchers and clinicians to compare a patient’s brain MRI with   population-derived data, using pattern analysis and machine  learning methods. The two studies will use MRI data from 23   international studies of approximately 18,000 individuals.
9. FDA Greenlights Siemens Healthineers’ 7T MRI for Clinical  Use
In   a first, the FDA has cleared a powerful 7-tesla MRI scanner for   clinical use. The machine getting  the go-ahead, limited to exams of the head and extremities, is Siemens   Healthineers’ Magnetom Terra. In an Oct. 12 announcement, the agency   says it gave the scanner the thumbs-up after reviewing the safety of its   radiofrequency subsystem through simulations  and computational modeling as well as experimental validation. Further,   Siemens supplied data from a study that compared the 7T machine’s images   of 35 healthy patients against images of the same anatomic structures   acquired with a predicate 3T device on the  market.
Robert   Ochs, PhD, of FDA’s Center for Devices and Radiological Health, said   that the more-than-doubled  static magnetic field strength of 7T over 3T “allows for better   visualization of smaller structures and subtle pathologies that may   improve disease diagnosis.” In a press release, Siemens says the scanner   has a dual-mode feature that allows the operator to  switch between a research mode and the newly 510(k)-cleared clinical   mode while safely storing research data and clinical images on separate   databases.
10. This Week in Congress
The   House and Senate are set to switch places this week as the Senate   returns from their weeklong  recess and the House departs for an in-district work period until Oct.   23. The Senate agenda starts with confirmation votes for Callista   Gingrich to be Ambassador to the Holy See and David Joel Trachtenberg to   be Principal Deputy Under Secretary of Defense,  which are scheduled for today and tomorrow, respectively. Senate   lawmakers are also likely to take up their version of a fiscal 2018   budget resolution (text)  after the House passed their budget earlier this month. Republicans are   seeking to complete the process in a timely fashion in order to   facilitate their ambitious goal of sending tax reform legislation to the   president’s desk before the end of the calendar  year. 
11. Upcoming Events
Wed. (10/18) 
    - 8:00am – Axios Event: Health Care Policy – Axios holds an event on next steps in healthcare policy, with  Sens. Lamar Alexander (R-TN), Tim Kaine (D-VA), and Bill Cassidy (R-LA). Details here.
- 8:00am-5:00pm – FDA Meeting: Metabolic Drugs  – The Food and Drug Administration (FDA) hosts a meeting of the Endocrinologic and Metabolic Drug Advisory Committee. Details here. 
- 1:00pm – NAM Meeting: Global Healthcare – The  National Academies of Medicine (NAM) hosts a meeting of the Committee on Improving Quality of Health Care Globally. Details here.
- 2:00pm-3:00pm – SAMHSA Webinar: Addiction – The  Substance Abuse and Mental Health Services Administration (SAMHSA) holds   a webinar that will highlight current innovations in developing the   nation’s addiction and mental health workforce. Details here.
Thurs. (10/19)
    - 10:00am- Hearing: Healthy Choices – The  Senate Committee on Health Education Labor and Pensions (HELP) convenes a   hearing entitled “Examining How Healthy Choices Can Improve Health   Outcomes and Reduce Costs. Details here.
- 1:30pm-3:00pm: MLN Webcast: QRUR Annual Reports  – The Medicare Learning Network (MLN) hosts a webcast for the 2016 Annual Quality and Resource Use Reports (QRURs). Details here. 
- 2:00pm – NAM Webinar: Organ Donation – The  National Academies of Medicine (NAM) holds a webinar to discuss opportunities for organ donor intervention research. Details here.
Fri. (10/20)
    - 8:30am-4:30pm  – FDA Workshop: Dermatological Drugs – The Food and Drug Administration (FDA) convenes a workshop on topical dermatological generic drug products. Details here. 
- 11:00am-1:00pm  – Public Meeting: Opioid Commission – The Office of National Drug Control Policy (ONDCP) holds a meeting of the President’s Commission on Combating Drug Addiction  and the Opioid Crisis. Details here.